Table 2.
Th1/Th2 and Th17/Treg related change in different treatments.
| Cell type | Treatment | Th1 change | Th2 change | Th17 change | Treg change | Other |
|---|---|---|---|---|---|---|
| CD4+ T cell from BALB/c mice (63) | 10 mM NAC (ROS scavenger) | IFN-γ ↑ | IL-4 ↓ IL-5 ↓ | NA | NA | STAT5Phosphorylation↓ |
| Human CD4+CD25– T cells (64) | Primed with macrophage from p47phox-CGD patients | IFN-γ ↑ | NA | IL-17↑ | CD4+CD25+Foxp3+ cell ↓ | NA |
| CD4+ CD45RO– T-cells under Th1- and Th17-skewing conditions (69) | Tempol (ROS scavenger) | IFN-γ+ cells ↑ | NA | IL-17+ cells ↑ | NA | NA |
Thayer et al. (70) immune cells whether receiving ROS clearing treatment, or primed with macrophage from CGD patients and healthy people. ↑: levels of cytokines or frequencies of cells are higher than control group. ↓: levels of cytokines or frequencies of cells are lower than control group.